期刊
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
卷 45, 期 4, 页码 819-843出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2016.06.008
关键词
Metformin; Glucose-lowering drug; Type 2 diabetes mellitus; Polycystic ovary syndrome; Delaying onset of type 2 diabetes mellitus; Gestational diabetes
资金
- NIDDK NIH HHS [T32 DK063687] Funding Source: Medline
Metformin is the recommended first-line oral glucose-lowering drug initiated to control hyperglycemia in type 2 diabetes mellitus. It acts in the liver, small intestines, and skeletal muscles with its major effect on decreasing hepatic gluconeogenesis. It is safe, inexpensive, and weight neutral and can be associated with weight loss. It can reduce microvascular complication risk and its use is associated with a lower cardiovascular mortality compared with sulfonylurea therapy. It is also used to delay the onset of type 2 diabetes mellitus, in treating gestational diabetes, and in women with polycystic ovary syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据